Relmada Therapeutics, Inc. - RLMD
About Gravity Analytica
Recent News
- 02.06.2025 - Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
- 12.09.2024 - Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
- 12.04.2024 - Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
- 11.19.2024 - Relmada Therapeutics to Present at Jefferies London Healthcare Conference
- 11.14.2024 - Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
- 11.07.2024 - Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update